




#7/A  
9-15-01  
M.L.

PATENT  
28341/6280NCP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	)	I hereby certify that this paper and the
Gurney and Bienkowski	)	documents referred to as enclosed
	)	therewith are being deposited with the
Serial No: 09/668,314	)	United States Postal Service as first
	)	class mail, postage prepaid, on April
Filed: September 22, 2000	)	30, 2001 in an envelope addressed to
	)	Commissioner for Patents
Title: Alzheimer's Disease Secretase, App	)	Washington, D.C. 20231.
Substrates Therefor, and Uses Therefor	)	
	)	
Group Art Unit: 1645	)	David A. Gass
	)	Reg. No. 38,153
Examiner: To be determined	)	Attorney for Applicants

**PRELIMINARY AMENDMENT AND STATEMENT UNDER 37 C.F.R. §1.825  
WITH SUBSTITUTE SEQUENCE LISTING AND EXECUTED DECLARATION**

Commissioner for Patents  
BOX MISSING PARTS  
Washington, D.C. 20231

Sir:

This amendment and the executed inventor's declaration submitted herewith are filed in response to the Notice to File Missing Parts mailed on February 22, 2001. Please amend the specification as follows:

**AMENDMENT**

In the Specification

Please replace the paragraph beginning at page 16 line 21 with the following paragraph:

In a preferred embodiment, the di-lysine-modified APP of the invention is a human APP. For example, human APP isoforms such as APP695, APP751, and APP770, modified to include the two lysines, are contemplated. In a preferred embodiment, the APP

AI  
cm.t